Biblio
Export 1657 results:
Author [ Title
Filters: First Letter Of Last Name is C [Clear All Filters]
“Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1083-1099, 2017.
, “Tau Protein Dysfunction after Brain Ischemia.”, J Alzheimers Dis, vol. 66, no. 2, pp. 429-437, 2018.
, “Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers.”, J Alzheimers Dis, vol. 63, no. 1, pp. 13-33, 2018.
, “TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study.”, J Alzheimers Dis, vol. 66, no. 4, pp. 1549-1558, 2018.
, “Telemedicine for Delivery of Care in Frontotemporal Lobar Degeneration During COVID-19 Pandemic: Results from Southern Italy.”, J Alzheimers Dis, vol. 76, no. 2, pp. 481-489, 2020.
, “Testing Hippocampal Memory in Prodromal Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 64, no. 2, pp. 349-353, 2018.
, “Testing Hippocampal Memory in Prodromal Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 64, no. 2, pp. 349-353, 2018.
, “Testing Hippocampal Memory in Prodromal Dementia with Lewy Bodies.”, J Alzheimers Dis, vol. 64, no. 2, pp. 349-353, 2018.
, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.
, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.
, “Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.”, J Alzheimers Dis, vol. 95, no. 1, pp. 213-225, 2023.
, “Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.”, J Alzheimers Dis, vol. 95, no. 1, pp. 213-225, 2023.
, “Tobacco Smoke Exposure Impairs Brain Insulin/IGF Signaling: Potential Co-Factor Role in Neurodegeneration.”, J Alzheimers Dis, vol. 50, no. 2, pp. 373-86, 2016.
, “Tobacco Smoke-Induced Brain White Matter Myelin Dysfunction: Potential Co-Factor Role of Smoking in Neurodegeneration.”, J Alzheimers Dis, vol. 50, no. 1, pp. 133-48, 2016.
, “Topographical APOE ɛ4 Genotype Influence on Cerebral Metabolism in the Continuum of Alzheimer's Disease: Amyloid Burden Adjusted Analysis.”, J Alzheimers Dis, vol. 54, no. 2, pp. 559-68, 2016.
, “Topographical Information-Based High-Order Functional Connectivity and Its Application in Abnormality Detection for Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 54, no. 3, pp. 1095-1112, 2016.
, “Topological Alterations and Symptom-Relevant Modules in the Whole-Brain Structural Network in Semantic Dementia.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1283-1297, 2017.
, “Topological Alterations and Symptom-Relevant Modules in the Whole-Brain Structural Network in Semantic Dementia.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1283-1297, 2017.
, “Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
, “Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
, “Toward the Automation of Diagnostic Conversation Analysis in Patients with Memory Complaints.”, J Alzheimers Dis, vol. 58, no. 2, pp. 373-387, 2017.
, “Tracking Cognitive Performance in the General Population and in Patients with Mild Cognitive Impairment with a Self-Applied Computerized Test (Brain on Track).”, J Alzheimers Dis, vol. 71, no. 2, pp. 541-548, 2019.
, “Transcranial Sonography in Neurodegenerative Diseases with Cognitive Decline.”, J Alzheimers Dis, vol. 61, no. 1, pp. 29-40, 2018.
, “Transcriptome Changes in the Alzheimer's Disease Middle Temporal Gyrus: Importance of RNA Metabolism and Mitochondria-Associated Membrane Genes.”, J Alzheimers Dis, vol. 70, no. 3, pp. 691-713, 2019.
, “Transferring cut-off values between assays for cerebrospinal fluid Alzheimer's disease biomarkers.”, J Alzheimers Dis, vol. 49, no. 1, pp. 187-99, 2016.
,